[go: up one dir, main page]

MX2019006449A - Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih). - Google Patents

Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).

Info

Publication number
MX2019006449A
MX2019006449A MX2019006449A MX2019006449A MX2019006449A MX 2019006449 A MX2019006449 A MX 2019006449A MX 2019006449 A MX2019006449 A MX 2019006449A MX 2019006449 A MX2019006449 A MX 2019006449A MX 2019006449 A MX2019006449 A MX 2019006449A
Authority
MX
Mexico
Prior art keywords
tricyclic heterocycle
heterocycle compounds
compounds useful
hiv integrase
integrase inhibitors
Prior art date
Application number
MX2019006449A
Other languages
English (en)
Other versions
MX384729B (es
Inventor
Yu Tao
T Waddell Sherman
H Graham Thomas
A Mccauley John
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2019006449A publication Critical patent/MX2019006449A/es
Publication of MX384729B publication Critical patent/MX384729B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos heterocíclicos tricíclicos de fórmula (I), y sales o profármacos farmacéuticamente aceptables de los mismos, en donde A, X, Y, Z, R1, R7A, R7B y R8 son como se define en la presente. La presente invención también se refiere a composiciones que comprenden por lo menos un compuesto heterocíclico tricíclico, y métodos de uso de los compuestos heterocíclicos tricíclicos para el tratamiento o prevención de una infección de VIH en un sujeto. (ver Fórmula).
MX2019006449A 2016-12-02 2017-12-01 Compuestos heterocíclicos tricíclicos útiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih). MX384729B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662429376P 2016-12-02 2016-12-02
PCT/US2017/064116 WO2018102634A1 (en) 2016-12-02 2017-12-01 Tricyclic heterocycle compounds useful as hiv integrase inhibitors

Publications (2)

Publication Number Publication Date
MX2019006449A true MX2019006449A (es) 2019-09-10
MX384729B MX384729B (es) 2025-03-14

Family

ID=62242756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006449A MX384729B (es) 2016-12-02 2017-12-01 Compuestos heterocíclicos tricíclicos útiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).

Country Status (11)

Country Link
US (1) US10934312B2 (es)
EP (1) EP3548031B1 (es)
JP (1) JP2020500866A (es)
KR (1) KR20190086017A (es)
CN (1) CN110062627A (es)
AU (1) AU2017367714B2 (es)
BR (1) BR112019011074B1 (es)
CA (1) CA3042314A1 (es)
MX (1) MX384729B (es)
RU (1) RU2749043C2 (es)
WO (1) WO2018102634A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250002769A (ko) 2018-05-31 2025-01-07 시오노기 앤드 컴파니, 리미티드 다환성 카바모일피리돈 유도체
AU2019277547B2 (en) 2018-05-31 2024-10-10 Shionogi & Co., Ltd. Polycyclic pyridone derivative
US11884683B2 (en) 2018-06-05 2024-01-30 Merck Sharp & Dohme Llc Tricyclic heterocycle compounds useful as HIV integrase inhibitors
CN119462659A (zh) 2019-03-22 2025-02-18 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其药学用途
AU2021225809B2 (en) 2020-02-24 2023-08-24 Gilead Sciences, Inc. Tetracyclic compounds for treating HIV infection
CN112047945B (zh) * 2020-09-10 2021-11-12 浙江大学 螺环吡啶酮衍生物及应用
JP7691494B2 (ja) 2020-09-30 2025-06-11 ギリアード サイエンシーズ， インコーポレイテッド 架橋三環式カルバモイルピリドン化合物及びその使用
HRP20231654T2 (hr) 2021-01-19 2025-01-03 Gilead Sciences, Inc. Supstituirani spojevi piridotriazina i njihove uporabe
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2181985B1 (en) 2001-08-10 2011-10-26 Shionogi & Co., Ltd. Antiviral Agent
HRP20040373B1 (en) 2001-10-26 2012-09-30 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
CA2463975A1 (en) 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
CA2472372C (en) 2002-01-17 2010-08-17 Melissa Egbertson Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
DK1509537T3 (da) 2002-04-26 2007-11-12 Gilead Sciences Inc Cellulær akkumulering af phosphonatanaloger af HIV-protease-inhibitorforbindelser og forbindelserne som sådanne
HRP20050593A2 (en) 2002-12-27 2006-03-31 Instituto di Ricerche di Biologia Molecolare P. An Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
US7135467B2 (en) 2003-01-13 2006-11-14 Bristol-Myers Squibb Company HIV integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
CN101146811B (zh) 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
ES2567197T3 (es) 2005-04-28 2016-04-20 Viiv Healthcare Company Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH
JP5131689B2 (ja) * 2005-10-27 2013-01-30 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
US7897593B2 (en) 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
MX2012004426A (es) 2009-10-13 2012-07-30 Elanco Animal Health Ireland Inhibidores macrociclicos de integrasa.
JP5739517B2 (ja) 2010-04-02 2015-06-24 ヤンセン・アールアンドデイ・アイルランド 大環状インテグラーゼ阻害剤
WO2014099586A1 (en) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
US9493479B2 (en) * 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
WO2014183532A1 (en) 2013-05-17 2014-11-20 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
US9951079B2 (en) * 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2015089847A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
EP3144311A4 (en) * 2014-05-16 2018-01-03 Shionogi & Co., Ltd. Tricyclic heterocyclic derivative having hiv replication-inhibiting effect
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors

Also Published As

Publication number Publication date
US20200017524A1 (en) 2020-01-16
BR112019011074B1 (pt) 2021-01-19
EP3548031B1 (en) 2023-07-19
JP2020500866A (ja) 2020-01-16
KR20190086017A (ko) 2019-07-19
RU2019116590A3 (es) 2021-01-26
EP3548031A1 (en) 2019-10-09
RU2019116590A (ru) 2021-01-11
US10934312B2 (en) 2021-03-02
BR112019011074A2 (pt) 2019-08-20
AU2017367714A1 (en) 2019-05-16
RU2749043C2 (ru) 2021-06-03
EP3548031A4 (en) 2020-06-03
CN110062627A (zh) 2019-07-26
WO2018102634A1 (en) 2018-06-07
AU2017367714B2 (en) 2020-11-12
MX384729B (es) 2025-03-14
CA3042314A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2019006449A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).
TN2016000090A1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors.
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
PH12018500065B1 (en) Oxysterols and methods of use thereof
EA033436B1 (ru) Производные 5-фенокси-3н-пиримидин-4-она и их применение в качестве ингибиторов обратной транскриптазы вич
PH12018500061A1 (en) Oxysterols and methods of use thereof
NZ703064A (en) Inhibitors of hepatitis c virus
WO2014172188A3 (en) 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
DK2997033T3 (da) Kondenserede tricykliske heterocykliske forbindelser som hiv- integrasehæmmere
PH12017502254B1 (en) Pyrazole derivative or pharmaceutically acceptable salt thereof
GEP20196952B (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors